Comments
Biocon Ltd said on Tuesday that it agreed to buy a 7.7 per cent stake in its research services business from a unit of GE Capital for Rs 215 crore ($35.48 million).
Biocon said it would buy the stake in unit Syngene, which is involved in pharmaceutical contract research and manufacturing, from GE Equity International Mauritius.
Biocon had previously said it planned to take Syngene public, but has not given a timeline.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.